Journals / Gülhane Tıp Dergisi / 2015 / Cilt: 57 - Sayı: 1

Intermedin/adrenomedullin 2'nin insan platelet agregasyonu üzerine in vitro etkileri

In vitro effect of intermedin/adrenomedullin 2 on platelet aggregation in human

Pages
41–43
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This in vitro study suggested that IMD/AM2 had no effect on platelet aggregation in a dose-dependent manner.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Intermedin/Adrenomedullin 2 (IMD/AM2) is a novel peptide related to the calcitonin gene-related peptide family.
📊
Key Findings & Data:This in vitro study was designed to the effect of IMD/AM2 on platelet aggregation with several platelet aggregation agents in the healthy volunteers.
💡
Conclusion & Impact:This in vitro study suggested that IMD/AM2 had no effect on platelet aggregation in a dose-dependent manner.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Intermedin/Adrenomedullin 2 (IMD/AM2) is a novel peptide related to the calcitonin gene-related peptide family. It is a vascular regulatory factor of homeostasis and a vital endogenous protective factor against vascular diseases. This in vitro study was designed to the effect of IMD/AM2 on platelet aggregation with several platelet aggregation agents in the healthy volunteers. The study was carried out on 7 healthy volunteers. Blood samples were centrifuged to prepare platelet-rich plasma and platelet-poor plasma. The platelet-rich plasma was diluted with the platelet poor plasma to yield test platelet-rich plasma with a final platelet count of 300,000±25,000 platelets L-9. Three concentration of IMD/AM2 solutions were prepared that would result in 10-8, 10-7, and 10-6 M. Each concentration of IMD/AM2 was incubated with platelet-rich plasma at 37 ?C during one hour. Platelet aggregation studies were carried out in platelet-rich plasma using 3?g ml-1 collagen, 10?M ADP, and 10?M epinephrine. In addition, spontaneous aggregation was performed for each concentration of IMD/AM2 incubated platelet-rich plasma. Compared to control, pre-incubation with all dilutions of IMD/AM2 had no detectable effect on platelet aggregation response induced collagen, ADP, epinephrine, and no detected spontaneous aggregation. The platelet aggregation amplitudes and slopes were statistically similar among all groups by the aggregation test. This in vitro study suggested that IMD/AM2 had no effect on platelet aggregation in a dose-dependent manner.

Özet

İntermedin/Adrenomedullin (IMD/AM2) kalsitonin genle ilişkili peptid ailesinin yeni bir üyesidir. Homeostaz için bir vasküler düzenleyici ve vasküler hastalıklara karşı önemli bir endojen koruyucu faktördür. Bu in vitro çalışma IMD/AM2'nin sağlık gönüllüler üzerinde çeşitli pletelet agregan ajanlar ile trombosit agregasyonu üzerinde etkisini araştırmak için tasarlanmıştır. Bu çalışma 7 sağlıklı gönüllü üzerinde gerçekleştirilmiştir. Kan örnekleri santrifüje edilerek trombositten zegin ve trombositten fakir plazma elde edildi. Trombositten zengin plazma, trombositten fakir plazma ile dilüe edilerek son trombosit sayısının 300,000±25,000 platelets L-9 olduğu trombositten zengin plazma elde edildi. IMD/AM2' nin 10-8, 10-7, and 10-6 M olacak şekilde 3 konsantrasyonu hazırlandı. IMD/AM2' nin her bir konsantrasyonu bir saat süreyle 37 ?C'de trombositten zengin plazma ile inkübe edildi. Trombosit agregasyon çalışmalara trombositten zengin plazma ile 3?g ml-1 kollajen, 10?M ADP ve 10?M epinephrine kullanılarak yapıldı. Ayrıca IMD/ AM2' nin her bir konsantrasyonu için spontan agregasyon trombositten zengin plazma inkübasyonu ile çalışıldı. Kontrol grubu ile karşılaştırıldığında kollajen, ADP, epinefrin indüksiyonu ile IMD/AM2' nin tüm dilüsyonlarda yapılan preinkübasyonunun trombosit agregasyonu üzerine saptanabilir cevabı ile spontan agregasyon etkisi yoktur. Agregasyon testinde trombosit agregasyon amplitütleri ve eğrileri tüm gruplarda istatistiksel olarak birbirine benzerdir. Bu in vitro çalışma doz bağımlı bir şekilde IMD/AM2' nin trombosit agregasyonu üzerine etkisi olmadığını göstermiştir.

🔖

Cite This Article

DOĞANCI, S., YILDIRIM, V., ÖZGÜR, G., YILDIRIM, M., ERTAŞ, Z., ÇETİN, T., GÜMÜŞEL, B., AVCU, F. (2015). Intermedin/adrenomedullin 2'nin insan platelet agregasyonu üzerine in vitro etkileri. Gülhane Tıp Dergisi, Cilt: 57 - Sayı: 1, 41–43. https://ajindex.com/articles/199157

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Doganci S, Yildirim V, Bolcal C, Demirkilic U, Ozal E, Ak- dag E, Arslan M, Gumusel B, Lippton H. Intermedin (IMD/ AM2) dilates the pig coronary vascular bed through relea- se of nitric oxide. Turkish J Thorac Cardiovasc Surg 2011; 19: 242-246.
  2. Ni X, Zhang J, Tang C, Qi Y. Intermedin/adrenomedullin2: an autocrine/paracrine factor in vascular homeostasis and disease. Sci China Life Sci 2014; 57: 781-9.
  3. Marutsuka K, Hatakeyama K, Yamashita A, Sato Y, Sumi- yoshi A, Asada Y. Adrenomedullin augments the release and production of tissue factor pathway inhibitor in human aortic endothelial cells. Cardiovasc Res 2003; 57: 232- 237. Parlapiano C, Paoletti V, Campana E, Labbadia G, Gio- vanniello T, Califano F, Pantone P, Clemente G, Donna- rumma L, Musca A. Adrenomedulline assay and its clinical significance. Eur Rev Med Pharmacol Sci 1999; 3:53-61.
  4. Kandilci HB, Gumusel B, Lippton H. Intermedin/adreno- medullin-2 (IMD/AM2) relaxes rat main pulmonary arterial rings via cGMP-dependent pathway: role of nitric oxide and large conductance calcium-activated potassium channels (BK(Ca)). Peptides 2008; 29: 1321-8. Noé L, Peeters K, Izzi B, Van Geet C, Freson K. Regula- tors of platelet cAMP levels: clinical and therapeutic impli- cations. Curr Med Chem 2010; 17: 2897-2905.
  5. Schiller NK, Champion HC, Hugghins SY, Timothy AM, Murphy WA, Coy DH, Peter JR, Kadowitz PJ, McNama- ra DB. Adrenomedullin Does Not Inhibit Human Platelet Aggregation. J Cardiovasc Pharmacol Ther 1998; 3: 223- 228. Ural AU, Yilmaz MI, Avcu F, Yalcin A. Treatment with ceri- vastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system compo- nents. Int J Hematol 2002; 76: 279-283.
  6. Kaptan K, Erinç K, Ifran A, Yildirim V, Uzun M, Beyan C, Işik E. Levosimendan has an inhibitory effect on platelet function. Am J Hematol 2008; 83: 46-49.
  7. Kose EA, Nevruz O, Honca M, Yildirim V. In vitro effect of dexmedetomidine on platelet aggregation. Braz J Anest- hesiol 2013; 63: 415-418.
  8. Li P, Sun HJ, Han Y, Wang JJ, Zhang F, Tang CS, Zhou YB. Intermedin enhances sympathetic outflow via recep- tor-mediated cAMP/PKA signaling pathway in nucleus tractus solitarii of rats. Peptides 2013; 47: 1-6.
  9. Lang-Rollin I, Schurek JO, Lang RE. Platelet-induced inhi- bition of adrenomedullin secretion. Eur J Pharmacol 2001 14; 427: 115-118.